Free Product Added!

All ProductsPainCold & FluDigestionSleep & StressAllergyMedicine CabinetSaved CabinetsPre-Made CabinetClean Medicine Our StoryStore LocatorHealthcare Professional NetworkFrequently Asked QuestionsLogin

Contact

If you have a question or comment feel free to give us a ring at 1-855-GENEXA-1, or text us at 310-254-2339.

We’re available Monday through Friday, 8am-5pm (PST).

Genexa's Pediatrician Survey

Pediatricians prefer Genexa Kids' Pain & Fever over Children's Tylenol® Pain + Fever Liquid Products for their own children based upon comparing ingredients.

The claim was substantiated, in May of 2021, using a random sample of pediatricians from all over the country. Each pediatrician had children between the ages of 2 and 11. All the pediatricians said they have used, or would be willing to use, an OTC acetaminophen product for treating their own children’s pain and fever.

Each pediatrician was shown the front of the packaging, as well as a list of the corresponding ingredients, for Genexa’s Kids’ Pain & Fever product and each of the Children’s Tylenol® Pain + Fever liquid products. They were asked based ONLY upon their review of the ingredients in each product, which, if any, they would prefer to give to their own children. A large majority of the pediatricians selected Genexa’s product over Tylenol’s products (Children's Tylenol® Pain + Fever Oral Suspension Cherry Flavor, Children's Tylenol® Pain + Fever Oral Suspension Grape Flavor, Children's Tylenol® Pain + Fever Oral Suspension Bubblegum Flavor, Children's Tylenol® Pain + Fever Oral Suspension Strawberry Flavor, Children's Tylenol® Pain + Fever Oral Suspension Dye-Free Cherry Flavor).*

*The error range around these percentages is ± 5.4 percentage points. If all 5.4 percentage points were at the expense of Genexa Kids’ Pain & Fever and all went to a Children’s Tylenol Pain + Fever product, then results would show 62.7% preferring Genexa Kids’ Pain & Fever and 31.7% preferring Children’s Tylenol Pain + Fever Oral Suspension overall, leaving a meaningful percentage still favoring Genexa.